CLINICAL_TRIALS
trial_result
· 2015-03-31
Clinical Trial Update: Phase 3 IGIV, 10% in Alzheimer´s Disease [Phase 3]
Summary
Phase 3 trial of intravenous immunoglobulin (IGIV) in Alzheimer’s disease was terminated with posted results.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Baxalta now part of Shire | Conditions: Alzheimer´s Disease | Phase 3 | Status: TERMINATED | Results posted: 2015-03-31